Pharmacological postconditioning of the rabbit heart with non-selective, A1, A2A and A3 adenosine receptor agonists

Abstract

Objectives We investigated the effects of novel selective and non-selective adenosine receptor agonists (ARs) on cardioprotection. Methods Male rabbits divided into six groups were subjected to 30-min heart ischaemia and 3-h reperfusion: (1) control group, (2) postconditioning (PostC) group, (3) group A: treated with the non-selective agonist (S)-PHPNECA, (4) group B: treated with the A1 agonist CCPA, (5) group C: treated with the A2A agonist VT 7 and (6) group D: treated with the A3 agonist AR 170. The infarcted (I) and the areas at risk (R) were estimated as %I/R. In additional rabbits of all groups, heart samples were taken for determination of Akt, eNOS and STAT 3 at the 10th reperfusion minute. Key findings (S)-PHPNECA and CCPA reduced the infarct size (17.2±2.9% and 17.9±2.0% vs 46.8±1.9% in control, P<0.05), conferring a benefit similar to PostC (26.4±0.3%). Selective A2A and A3 receptor agonists did not reduce the infarct size (39.5±0.8% and 38.7±3.5%, P=NS vs control). Akt, eNOS and STAT 3 were significantly activated after non-selective A1 ARs and PostC. Conclusions Non-selective and A1 but not A2A and A3 ARs agonists are essential for triggering cardioprotection. The molecular mechanism involves both RISK and the JAK/STAT pathways. © 2014 Royal Pharmaceutical Society.